1. Academic Validation
  2. C-terminal deletions in the ALAS2 gene lead to gain of function and cause X-linked dominant protoporphyria without anemia or iron overload

C-terminal deletions in the ALAS2 gene lead to gain of function and cause X-linked dominant protoporphyria without anemia or iron overload

  • Am J Hum Genet. 2008 Sep;83(3):408-14. doi: 10.1016/j.ajhg.2008.08.003.
Sharon D Whatley 1 Sarah Ducamp Laurent Gouya Bernard Grandchamp Carole Beaumont Michael N Badminton George H Elder S Alexander Holme Alexander V Anstey Michelle Parker Anne V Corrigall Peter N Meissner Richard J Hift Joanne T Marsden Yun Ma Giorgina Mieli-Vergani Jean-Charles Deybach Hervé Puy
Affiliations

Affiliation

  • 1 Department of Medical Biochemistry and Immunology, University Hospital of Wales and, School of Medicine, Cardiff University, Cardiff CF14 4XN, UK.
Abstract

All reported mutations in ALAS2, which encodes the rate-regulating Enzyme of erythroid heme biosynthesis, cause X-linked sideroblastic anemia. We describe eight families with ALAS2 deletions, either c.1706-1709 delAGTG (p.E569GfsX24) or c.1699-1700 delAT (p.M567EfsX2), resulting in frameshifts that lead to replacement or deletion of the 19-20 C-terminal residues of the Enzyme. Prokaryotic expression studies show that both mutations markedly increase ALAS2 activity. These gain-of-function mutations cause a previously unrecognized form of porphyria, X-linked dominant protoporphyria, characterized biochemically by a high proportion of zinc-protoporphyrin in erythrocytes, in which a mismatch between protoporphyrin production and the heme requirement of differentiating erythroid cells leads to overproduction of protoporphyrin in amounts sufficient to cause photosensitivity and liver disease.

Figures